- Home
- SRTS vs ABVC Comparison
SRTS vs ABVC Comparison
Compare SRTS & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | ABVC |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5M | 58.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRTS | ABVC |
|---|---|---|
| Price | $3.81 | $2.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 59.9K | ★ 75.8K |
| Earning Date | 02-04-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,609,000.00 | $797,916.00 |
| Revenue This Year | N/A | $735.18 |
| Revenue Next Year | $27.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 56.52 |
| 52 Week Low | $3.03 | $0.40 |
| 52 Week High | $9.08 | $5.48 |
Technical Indicators
Market Signals| Indicator | SRTS | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 47.51 |
| Support Level | $3.67 | $1.97 |
| Resistance Level | $3.92 | $2.47 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 50.93 | 59.63 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.